Sažetak | Objectives: The aim of the presented study was to analyze clinical data of patients with
symptomatic malignant pleural effusion due to pleural carcinosis hospitalized at the REGIOMED
Clinics and to evaluate and compare outcomes of different local surgical treatment modalities
with regards to effectiveness, survival, morbidity as well as duration of hospital stay.
Materials and methods: Patients with cytologically or histopathologically proven pleural
carcinosis and malignant pleural effusion, hospitalized at any of the REGIOMED Clinics facilities
in Germany, from January 2018 to December 2020, were included in this retrospective
observational chart-based study. All patients were suffering from dyspnea. Patients were divided
into groups according to the type of treatment they received. The aforesaid treatment
options are the following: VATS (video-assisted thoracoscopic surgery) pleurodesis (mechanical
or chemical) alone or in combination with an indwelling pleural catheter (IPC), combination
of VATS and indwelling pleural catheter (IPC), or sole management with an indwelling
pleural catheter (IPC).
Results: The study included 91 patients, aged between 38 and 90 years. Mean survival time
was 138.3 days. No significant differences could be detected between treatment groups regarding
the outcome treatment failure, neither initially (P=0.436), nor late treatment failure
(P=0.068). In the VATS pleurodesis IPC group, patients experienced significantly more complications
compared to the other treatment modalities (OR:3.288, P=0.026). Hypoalbuminemia,
systemic therapy as well as successful pleurodesis (r=-0.322, P=0.008; r=0.310,
P=0.011; r=0.247, P=0.044 respectively) significantly correlated with survival. In multiple
linear regression, hypoalbuminemia persisted as independent predictor of survival (P=0.031).
The type of intervention patients underwent showed significant difference regarding duration
of hospital stay (P=0.017).
Conclusion: Treatment should be individualized and led by an assessment of the patient’s
prognosis and driven by a balance of the expected benefit and morbidity of the proposed procedure
as well as individual desires of the patient. The ideal method for treating malignant
pleural effusion should be simple, effective, and inexpensive, with minimal disturbance to the
patient. The survival time is short and expressed in months for patients with MPE. With the
continued efforts to improve patient-centered endpoints, the combination of therapies offers
promising alternatives over individual therapy alone. |
Sažetak (hrvatski) | Cilj: Cilj studije bio je analiza kliničkih podataka pacijenata s malignim pleuralnim izljevom
zbog pleuralne karcinoze, hospitaliziranima u Klinici REGIOMED, te procjena i usporedba
rezultata raznih modaliteta lokalnih kirurških tretmana u vezi djelotvornosti, preživljenja,
smrtnosti, kao i trajanja hospitalizacije.
Materijali i metode: U ovu retrospektivnu opservacijsku temeljenu na karticama uključeni su
pacijenti s citološki ili histopatološki dokazanom pleuralnom karcinozom i malignim
pleuralnim izljevom, hospitalizirani u nekoj od jedinica Klinike REGIOMED u Njemačkoj od
siječnja 2018. do prosinca 2020. Svi pacijenti patili su od zaduhe. Gore spomenute opcije
tretmana su slijedeće: VATS (videoasistirana torakoskopska kirurška) pleurodeza (mehanička
ili kemijska) sama ili u kombinaciji s tuneliranim pleuralnim kateterom (IPC), kombinacija
VATS i tuneliranog pleuralnog katetera (IPC), ili samo tunelirani pleuralni kateter (IPC).
Rezultati: Studija je uključila 91 pacijenta, starosti između 38 i 90 godina. Srednje vrijeme
preživljenja bilo je 138,3 dana. U skupini VATS pleurodeza IPC, pacijenti su imali značajno
više komplikacija u odnosu na druge modalitete liječenja (OR:3,288, P=0,026).
Hipoalbuminemija, sistemska terapija i uspješna pleurodeza (r=0,322, P=0,008; r=0,310,
P=0,011; odnosno r=0,247, P=0,044) značajno su korelirali s preživljenjem. U višestrukoj
linearnoj regresiji, hipoalbuminemija ustrajala je kao neovisan pretkazivač preživljenja
(P=0,031). Vrsta tretmana kojem su pacijenti bili podvrgnuti pokazala je značajnu razliku u
vezi trajanja hospitalizacije (P=0,017).
Zaključak: Liječenje mora biti individualizirano i vođeno procjenom pacijentove prognoze te
ravnotežom očekivane koristi i smrtnosti predloženog postupka kao i pacijentovim
individualnim željama. Idealna metoda liječenja malignog pleuralnog izljeva treba biti
jednostavna, djelotvorna i ne skupa, s minimalnim uznemiravanjem pacijenta. Vrijeme
preživljenja kod pacijenata s MPE je kratko i izraženo u mjesecima. Uz stalne napore k
poboljšanju ciljeva usredotočenih na pacijenta, kombinacija terapija nudi obećavajuće
alternative samo individualnim terapijama. |